Spray-dried mucoadhesive microparticles based on S-protected thiolated hydroxypropyl-β-cyclodextrin for budesonide nasal delivery.
Allergic Rhinitis
Budesonide
Hydroxypropyl- β -cyclodextrin
Microparticles
Mucoadhesion
Nasal delivery
Spray-drying
Thiomers
Journal
International journal of pharmaceutics
ISSN: 1873-3476
Titre abrégé: Int J Pharm
Pays: Netherlands
ID NLM: 7804127
Informations de publication
Date de publication:
15 Jun 2021
15 Jun 2021
Historique:
received:
17
01
2021
revised:
18
05
2021
accepted:
19
05
2021
pubmed:
25
5
2021
medline:
22
6
2021
entrez:
24
5
2021
Statut:
ppublish
Résumé
Budesonide (BUD) is used as first choice therapy for the treatment of allergic rhinitis, a chronic allergic-immune condition with an increased incidence in the pediatric population. The main problem of BUD nasal formulations is related to its poor aqueous solubility (S
Identifiants
pubmed: 34029665
pii: S0378-5173(21)00533-0
doi: 10.1016/j.ijpharm.2021.120728
pii:
doi:
Substances chimiques
Sulfhydryl Compounds
0
2-Hydroxypropyl-beta-cyclodextrin
1I96OHX6EK
Budesonide
51333-22-3
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
120728Informations de copyright
Copyright © 2021 Elsevier B.V. All rights reserved.